Veltuzumab
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | CD20 |
| Identifiers | |
| CAS Number | 728917-18-8 |
| ATC code | none |
| Chemical data | |
| Formula | C6458H9918N1706O2026S46 |
| Molar mass | 145.3 kDa[[Script error: No such module "String".]] |
Veltuzumab is a monoclonal antibody which is being investigated for the treatment of non-Hodgkin's lymphoma.[1][2] As of October 2009[update], it is undergoing Phase I/II clinical trials.[3][4]
This drug was developed by Immunomedics, Inc.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
- ↑ Rossi, E. A.; Goldenberg, D. M.; Cardillo, T. M.; Stein, R.; Chang, C. -H. (2009). "CD20-targeted tetrameric interferon- , a novel and potent immunocytokine for the therapy of B-cell lymphomas". Blood. 114 (18): 3864. doi:10.1182/blood-2009-06-228890. PMC 2773491 Freely accessible. PMID 19710501.
- ↑ ClinicalTrials.gov NCT00596804 Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
- ↑ ClinicalTrials.gov NCT00546793 Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from October 2009
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- 2Fix
- Monoclonal antibody stubs
